News
Helium Special Situations increases interest in Scancell
17th November 2011Holdings in Company
The Company announces that it has received notification that Helium Special Situations Fund Limited has increased its beneficial interest in Scancell Holdings to 17,586,940 ordinary shares of 0.1 pence each which represents approximately 9.06 per cent of the issued capital of the Company.
For further information contact:
Scancell Holdings Plc
Professor Lindy Durrant/Dr Richard Goodfellow
+ 44 (0)207 245 1100
Hansard Communications- Financial PR
Adam Reynolds/Guy McDougall
+ 44 (0)207 245 1100
Zeus Capital - Nominated Adviser
Ross Andrews/Tom Rowley
+ 44 (0)161 831 1512
XCAP Securities Plc - Broker
Jon Belliss/ Adrian Kirk
+44 (0) 207 101 7070
Press coverage
- Richard Goodfellow - why we want to work with patient advocacy groups
- What I Learned From the CEO of an Immunotherapy Start-Up
- Biotech blockbusters
- Is this the pioneering DNA vaccine we've been waiting for?
- Electric jab in your arm that fights skin cancer
- Finanz und Wirtschaft 5th June 2013
- Finanz und Wirtschaft 12th June 2013
- ECOreporter 14th August 2013
- Scancell And OncoSec looking good with melanoma immunotherapies
- Why checkpoint inhibitors need help June 2014
Webcasts, Interviews and Media Coverage
Scancell recruits deal maker to take over as CEO
Executive chairman John Chiplin said new CEO Dr Cliff Holloway's extensive experience and accomplishments speak volumes
Tue, 10 Oct 2017 08:24:00
Scancell on the lookout for partners after year of “significant progress”
“We are continuing to explore a number of funding options to ensure that we have the resources to progress these programmes through their next phase”
Wed, 13 Sep 2017 06:21:00
Scancell presents Moditope data at prestigious cancer conference
Chief scientific officer Lindy Durrant presented two posters at the International Cancer Immunotherapy conference in Germany on Friday
Mon, 11 Sep 2017 09:25:00